This study is the first to show a clonal advantage in RTs post-OLT compared to PTs in HCC, where Wnt/β-catenin signaling activation and tumor suppressor gene CDKN2A inactivation occurs in both tumors. The gene discussed is CDKN2A; the disease is hepatocellular carcinoma.